Virtual Meetings 2020

Meet The Professor: Management of Gynecologic Cancers

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

Michael J Birrer, MD, PhD
Vice Chancellor, UAMS
Director, Winthrop P Rockefeller Cancer Institute
Director, Cancer Service Line
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Robert L Coleman, MD
Chief Scientific Officer
US Oncology Research
Gynecologic Oncology
McKesson
The Woodlands, Texas

Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Vall d'Hebron Institute of Oncology
Hospital Universitari Vall d’Hebron
Vall d’Hebron Barcelona Hospital Campus
Barcelona, Spain

David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director
Gynecologic Oncology Phase I Program
The Ohio State University and
The James Cancer Center
Columbus, Ohio

Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts



Matthew A Powell, MD
Professor and Chief
Division of Gynecologic Oncology
Washington University School of Medicine
St Louis, Missouri

Brian M Slomovitz, MD
Professor, Department of Obstetrics and Gynecology
Florida International University
Miami, Florida

Krishnansu S Tewari, MD
Professor and Division Director
Division of Gynecologic Oncology
University of California, Irvine
Irvine, California

Professor Ignace Vergote
Chairman, Department of Obstetrics and Gynaecology
Gynaecological Oncologist
Leuven Cancer Institute
University Hospital Leuven
Leuven, Belgium

SERIES MODERATOR
Neil Love, MD
Research To Practice

Agenda

Each 1-hour session will include 5 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for gynecologic cancers. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist case presentations
  • Interactive audience polling and extensive Q&A

    Module 1: Anti-PD-1/PD-L1 Monotherapy for Metastatic Endometrial Cancer

    Module 2: Immune Checkpoint Inhibitors in Combination with Other Systemic Therapies for Metastatic Endometrial Cancer

    Module 3: Current Indications for and Future Role of Anti-PD-1/PD-L1 Antibodies in Cervical Cancer

    Module 4: Investigative Approaches with Immune Checkpoint Inhibitors for Ovarian Cancer

    Module 5: Other Novel Agents and Strategies in Gynecologic Cancers

Target Audience
These activities are intended for gynecologic oncologists, medical oncologists, gynecologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gynecologic cancers.

Learning Objectives

  • Describe the biologic rationale for, published research data with and ongoing evaluation of immune checkpoint inhibitors in the management of ovarian cancer (OC), endometrial cancer (EC) and cervical cancer (CC), and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
  • Recognize the importance of microsatellite instability (MSI) testing for patients with OC, EC and CC, and identify the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high (MSI-H) disease.
  • Appraise the clinical research supporting the FDA approval of anti-PD-1 monotherapy for progressive PD-L1-positive metastatic CC, and counsel appropriate patients about the risks and potential benefits of this approach.
  • Recall available data with anti-PD-1/PD-L1 antibodies for MSI-H and microsatellite-stable recurrent EC, and appreciate ongoing research attempting to further define the role of these agents in this disease.
  • Assess the recent FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced EC that is not MSI-H/mismatch repair-deficient who have experienced disease progression after systemic therapy but are not candidates for curative surgery or radiation therapy in order to optimally integrate this novel regimen into current clinical management algorithms.
  • Recognize the incidence of tissue factor expression in patients with CC and other gynecologic cancers, and consider the potential role of novel agents designed to exploit this therapeutic target.
  • Review the mechanisms of action, emerging efficacy data and toxicity profiles of novel targeted agents under investigation in OC, CC and EC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.


Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Slomovitz has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr BirrerConsulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company. Dr ColemanAdvisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics. Dr OakninAdvisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genmab, ImmunoGen Inc, PharmaMar, Roche Laboratories Inc, Tesaro, A GSK Company; Paid Travel: AstraZeneca Pharmaceuticals LP, PharmaMar, Roche Laboratories Inc. Dr O'MalleyAdvisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure, Regeneron Pharmaceuticals Inc, Seattle Genetics, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Botherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seattle Genetics, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc. Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc. Dr PensonAdvisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Care4ward (unpaid), Clovis Oncology, Curio Science, Eisai Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, NewLink Genetics, Nexus Group Global, Pieris Pharmaceuticals Inc, Roche Laboratories Inc, Sutro Biopharma, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company, Vascular Biogenics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, Vascular Biogenics; Data and Safety Monitoring Board/Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP. Dr PowellConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Tesaro, A GSK Company. Dr TewariAdvisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Tesaro, A GSK Company; Contracted Research (Institution Only): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Roche Laboratories Inc, Tesaro, A GSK Company. Prof VergoteAdvisory Committee: Amgen (Europe) GmbH, AstraZeneca Belux, Carrick Therapeutics, Clovis Oncology, Debiopharm Group, Deciphera Pharmaceuticals Inc, Doctaforum Servicios Sl, F Hoffmann-La Roche Ltd, Genmab, GlaxoSmithKline, ImmunoGen Inc, MSD Belgium, OCTIMET Oncology NV, Oncoinvent AS, PharmaMar, Roche Laboratories Inc, SOTIO as, Takeda Oncology, Tesaro, A GSK Company, Verastem Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Contracted Research: Amgen Inc, Genmab, Oncoinvent AS, Roche Laboratories Inc; Paid Travel: Amgen Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Roche Laboratories Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Commercial Support
These activities are supported by educational grants from Eisai Inc, Merck, Seattle Genetics and Tesaro, A GSK Company.